Viva voce questions that can asked on post tb fibrocavity disease case presentation tell me everything don't miss anything

Reading File

This is a broad viva-preparation set. I can cover it systematically as:

Case framing and definition of post-TB fibrocavitary disease
Focused history, examination, and presentation format
Radiology: chest X-ray, HRCT, differential patterns
Microbiology and distinguishing active TB from healed sequelae
Differential diagnoses, including malignancy, NTM, fungal disease, bronchiectasis
Sequelae and complications: aspergilloma, chronic pulmonary aspergillosis, hemoptysis, pneumothorax, respiratory failure, pulmonary hypertension and cor pulmonale
Investigations and interpretation
Management: active/recurrent TB, airway disease, aspergillus disease, hemoptysis, rehabilitation, surgery and follow-up
Rapid-fire examiner cross-questions and common pitfalls

At a high level, the core viva issue is this: a residual cavity and fibrosis after prior TB do not by themselves prove active TB. The presentation must establish current disease activity, define structural lung damage and functional impairment, and actively exclude important alternatives or superadded disease, especially chronic pulmonary aspergillosis and lung cancer.

Asking for Preferences

Which section should I build into a detailed viva question-and-answer bank first?

This is a broad viva-preparation set. I can cover it systematically as:

Case framing and definition of post-TB fibrocavitary disease
Focused history, examination, and presentation format
Radiology: chest X-ray, HRCT, differential patterns
Microbiology and distinguishing active TB from healed sequelae
Differential diagnoses, including malignancy, NTM, fungal disease, bronchiectasis
Sequelae and complications: aspergilloma, chronic pulmonary aspergillosis, hemoptysis, pneumothorax, respiratory failure, pulmonary hypertension and cor pulmonale
Investigations and interpretation
Management: active/recurrent TB, airway disease, aspergillus disease, hemoptysis, rehabilitation, surgery and follow-up
Rapid-fire examiner cross-questions and common pitfalls

Tell me full details from exam points of view

Reading File

Finding Sources

Searching PubMed

"pulmonary tuberculosis" AND "post-tuberculosis lung disease"

Searching the Web

WHO tuberculosis module diagnosis treatment 2025 post tuberculosis lung disease chronic pulmonary aspergillosis

Finding Sources

Searching PubMed

"chronic pulmonary aspergillosis" AND tuberculosis

Searching the Web

post tuberculosis lung disease clinical standards chronic pulmonary aspergillosis diagnosis guidelines

Post-TB fibrocavitary disease: complete viva guide

The opening definition

Post-tuberculosis lung disease (PTLD) is chronic respiratory abnormality, with or without symptoms, attributable at least partly to previous pulmonary TB after completion of treatment. It includes fibrosis, residual cavities, volume loss, bronchiectasis, airway stenosis, pleural thickening, destroyed lung, airflow obstruction, and pulmonary vascular disease.

Post-TB fibrocavitary disease means residual fibrotic destruction and one or more cavities in the lung, usually upper-lobe predominant, following healed or previously treated pulmonary TB.

Important examiner point:
A fibrotic cavity in a person with past TB is not synonymous with active TB. Current active TB, drug-resistant TB, non-tuberculous mycobacterial infection, chronic pulmonary aspergillosis, bacterial infection, and lung cancer must be evaluated when symptoms or new radiological changes occur.

1. One-minute case presentation

“This is a ___-year-old man/woman with a history of microbiologically confirmed pulmonary tuberculosis treated in ___ year, who now presents with chronic cough with/without sputum, exertional breathlessness, constitutional symptoms, and/or hemoptysis for ___.

Examination shows features of volume loss and fibrosis involving the ___ hemithorax, such as chest asymmetry, reduced movement, tracheal shift to the affected side, reduced expansion, impaired percussion note, and bronchial breath sounds or coarse crackles.

Chest radiograph shows upper-zone predominant fibrotic opacities with volume loss, hilar elevation, traction bronchiectasis and a residual thick-walled cavity in ___.

My clinical diagnosis is post-tuberculosis fibrocavitary lung disease with ___ complication, while actively excluding recurrent active pulmonary TB, chronic pulmonary aspergillosis/aspergilloma, bronchiectasis with infection, NTM disease, and cavitating bronchogenic carcinoma.”

If there is hemoptysis, add:

“The immediate clinical concern is to assess the severity and source of hemoptysis, particularly bronchial-artery bleeding due to bronchiectasis, active TB, or a fungal ball within a residual cavity.”

2. Likely questions on terminology

Q. Is “post-TB fibrocavitary disease” a diagnosis?

It is a descriptive clinicoradiological diagnosis, not a final etiological diagnosis. It describes structural sequelae following TB. One must establish whether disease is healed and stable or whether there is active superadded pathology.

Q. What is a residual cavity?

A persistent air-containing space left after caseous necrosis drains through a bronchus and the surrounding lung heals by fibrosis. It may remain thin- or thick-walled and can be colonized by organisms, especially Aspergillus.

Q. What are the main forms of PTLD?

Fibrosis and fibrocalcific scars
Residual cavities
Traction bronchiectasis or post-infective bronchiectasis
Bronchial stenosis, broncholithiasis, and atelectasis
Pleural thickening, calcification, fibrothorax
Parenchymal destruction or destroyed lung
Obstructive, restrictive, or mixed ventilatory defect
Chronic respiratory failure
Pulmonary hypertension and cor pulmonale
Chronic pulmonary aspergillosis and aspergilloma
Recurrent infections and hemoptysis

Post-TB bronchiectasis remains an important cause of morbidity in TB-endemic settings. This is consistent with the pathology description in Robbins & Kumar Basic Pathology, Bronchiectasis section.

3. History taking: examiner checklist

A. Previous TB history

Ask specifically:

When was TB diagnosed?
Was it microbiologically confirmed?
- Sputum smear microscopy?
- NAAT/CBNAAT/Xpert?
- Culture and drug-susceptibility testing?
Site and extent of disease:
- Pulmonary or extrapulmonary?
- Cavitary disease at baseline?
- Unilateral or bilateral?
Treatment details:
- Which regimen?
- Duration?
- Regularity/adherence?
- Treatment interruption?
- Adverse drug effects?
Outcome:
- Declared cured/treatment completed?
- End-of-treatment sputum status?
- Previous recurrence or retreatment?
- Previous drug resistance?

Why ask? Incomplete, irregular, or failed treatment increases the probability of recurrent active TB and drug resistance.

B. Current respiratory symptoms

Cough: duration, dry/productive, amount and color of sputum
Fever, especially persistent low-grade fever
Night sweats
Weight loss, anorexia, fatigue
Dyspnea:
- mMRC grade
- Exercise limitation
- Orthopnea or paroxysmal nocturnal dyspnea
Wheeze
Pleuritic chest pain
Recurrent lower respiratory infections
Chest tightness or reduced exercise tolerance

C. Hemoptysis history

Ask in detail:

Is it true hemoptysis?
- Differentiate from hematemesis and bleeding from nose/oropharynx.
Quantity:
- Blood-streaked sputum
- Mild
- Moderate
- Large-volume or life-threatening hemoptysis
Frequency and duration
Fresh red blood or altered blood
Clots?
Preceded by cough?
Associated fever, purulent sputum, weight loss, breathlessness?
Prior similar episodes?
Anticoagulants, antiplatelets, NSAIDs?
Known fungal ball, bronchiectasis, or previous bronchial artery embolization?

Exam answer: Mortality in hemoptysis is primarily due to asphyxiation from airway flooding, not exsanguination.

D. History suggesting chronic pulmonary aspergillosis

Symptoms persisting for at least 3 months:
- Cough
- Hemoptysis
- Weight loss
- Fatigue
- Low-grade fever
- Breathlessness
A prior TB cavity
Increasing cavity size or a new intracavitary mass on imaging
Failure to improve with antibacterial therapy or empiric anti-TB therapy

A cavity with fungal ball is not automatically simple aspergilloma. Chronic pulmonary aspergillosis requires compatible chronic symptoms, radiology and microbiological/serological evidence, while excluding active TB and alternatives. A recent prospective post-TB study describes these diagnostic principles and the role of Aspergillus IgG in its CPA diagnostic criteria.

E. Symptoms suggesting other complications

Bronchiectasis

Daily purulent sputum
Recurrent fever or “chest infections”
Hemoptysis
Pleuritic pain

Chronic respiratory failure

Progressive dyspnea
Morning headache
Daytime somnolence
Confusion
Cyanosis

Pulmonary hypertension/cor pulmonale

Exertional syncope or chest pain
Pedal edema
Abdominal distension
Right upper-quadrant discomfort
Reduced exercise capacity

Lung cancer

New or changed cough
Weight loss out of proportion
Persistent or new hemoptysis
Hoarseness
Chest pain
Bone pain, headache, focal neurological deficit
Smoking history

F. Risk factors and comorbidities

Smoking and biomass smoke exposure
Diabetes mellitus
HIV status and antiretroviral treatment
Malnutrition
Steroid or other immunosuppressive therapy
COPD/asthma
Previous COVID-19 or chronic lung disease
Silicosis
Chronic kidney disease, liver disease
Occupational dust exposure
Contact with TB and household crowding

4. Examination: what to demonstrate

General examination

Look for:

Low BMI, muscle wasting, pallor
Fever
Digital clubbing:
- Bronchiectasis
- Lung cancer
- Chronic suppuration
- Chronic pulmonary aspergillosis
Cyanosis
Lymphadenopathy
Pedal edema
Raised JVP
Signs of chronic liver disease if relevant
Features of diabetes, HIV-related disease, or steroid use

Respiratory examination in unilateral fibrotic disease

Inspection

Reduced movement of affected hemithorax
Reduced chest expansion
Flattening or asymmetry of chest wall
Intercostal space crowding
Supraclavicular hollowing
Scars from prior thoracostomy/surgery
Dilated veins, if superior vena cava obstruction is suspected

Palpation

Reduced chest expansion on affected side
Trachea and apex beat shifted towards the side of volume loss
Tactile vocal fremitus may be variable:
- Increased over fibrosis/consolidation
- Decreased with pleural thickening, effusion, or destroyed lung

Percussion

Impaired or dull note over fibrosis/volume loss
Hyperresonance may occur over bullae, a large air-filled cavity, or compensatory emphysema

Auscultation

Bronchial breathing over fibrotic/consolidated area
Coarse inspiratory crackles from bronchiectasis
Amphoric breath sound over a large superficial patent cavity communicating with a bronchus
Reduced breath sounds over severe destruction/fibrothorax
Wheeze if coexistent airflow obstruction

Contralateral lung

Look for compensatory hyperinflation, emphysema, or contralateral crackles indicating bilateral involvement.

Cardiovascular examination

Specifically assess for cor pulmonale:

Raised JVP
Loud P2
Right ventricular heave
Tricuspid regurgitation murmur
Hepatomegaly
Ascites and pedal edema

5. How to interpret the chest X-ray

Typical post-TB fibrocavitary changes

Upper-zone or apical fibrotic opacities
Linear fibrotic bands
Volume loss
Upward displacement of hilum
Tracheal and mediastinal shift towards affected side
Elevated hemidiaphragm
Rib crowding
Pleural thickening or calcification
Traction bronchiectasis
Residual cavity, often thick-walled and upper lobe predominant
Calcified granulomas or hilar lymph nodes
Compensatory hyperinflation of remaining lung

Features that suggest active TB rather than inactive sequelae

New infiltrates or consolidation
New cavity or increase in cavity size
Thick irregular cavity wall with surrounding infiltrates
Tree-in-bud nodules on HRCT
Centrilobular nodules
New pleural effusion
Progressive radiological change on serial films
Constitutional symptoms and positive microbiology

Key viva line:
“Chest radiography cannot reliably distinguish active from inactive TB. Clinical correlation and microbiological evaluation are essential.”

Cavity wall: common viva question

Thin smooth wall

May suggest:

Healed cavity
Bulla
Pneumatocele
Cyst

Thick irregular wall

May suggest:

Active TB
Chronic pulmonary aspergillosis
Lung abscess
Cavitating carcinoma
NTM disease

But wall thickness alone is not diagnostic.

6. HRCT: why and what to look for

Q. Why do HRCT?

HRCT is the best imaging modality to define the extent and type of structural damage, identify bronchiectasis, characterize cavities, detect fungal ball, assess new nodules/mass, and guide bronchoscopy or intervention.

HRCT findings in PTLD

Fibrosis and parenchymal bands
Architectural distortion
Volume loss
Traction bronchiectasis
Cylindrical, varicose or cystic bronchiectasis
Residual cavities
Pleural thickening/fibrothorax
Mosaic attenuation and air trapping due to small-airway disease
Emphysema or bullae
Destroyed lung
Pulmonary artery enlargement suggesting pulmonary hypertension

CT features of aspergilloma

Intracavitary rounded soft-tissue opacity
Air crescent around the mass, often called the Monod sign
The mass may move with change in position, demonstrating that it is not attached to the cavity wall
Usually within a pre-existing upper-lobe TB cavity

CT features suggesting chronic pulmonary aspergillosis

One or more progressive cavities
Pericavitary infiltrates
Pleural thickening adjacent to a cavity
Fungal ball, with or without cavity expansion
Fibrosis and volume loss
New nodules or consolidation

CT features concerning for malignancy

Eccentric thick irregular cavity wall
Nodular inner margin
Mass lesion or mediastinal lymphadenopathy
Progressive lesion despite appropriate treatment
New lesion in a smoker or older patient

7. Differential diagnosis of a chronic cavity

Use the mnemonic: “TB, tumour, fungus, pus, vasculitis, emboli.”

Differential	Clues
Active/recurrent pulmonary TB	Fever, night sweats, weight loss, new infiltrates, positive NAAT/culture
Drug-resistant TB	Prior treatment, poor adherence, contact with DR-TB, persistent smear/culture positivity
NTM pulmonary disease	Bronchiectasis/cavities, repeatedly positive NTM cultures, negative TB NAAT
Chronic pulmonary aspergillosis	Prior cavity, chronic symptoms, hemoptysis, progressive cavity, positive Aspergillus IgG
Simple aspergilloma	Mobile fungal ball in a stable pre-existing cavity; often minimal symptoms except hemoptysis
Bacterial lung abscess	Fever, toxic state, productive cough, air-fluid level
Cavitating bronchogenic carcinoma	Older age, smoking, new unilateral cavity, mass/nodular wall, weight loss
Squamous-cell carcinoma	Most common bronchogenic carcinoma associated with cavitation
Nocardia	Immunocompromised patient, subacute infection
Actinomycosis	Chronic infection mimicking TB or malignancy
Granulomatosis with polyangiitis	ENT/renal features, multiple nodules/cavities, ANCA may support but does not establish diagnosis
Septic emboli	Multiple peripheral cavitating nodules, fever, endocarditis risk
Pulmonary infarction	Vascular risk, pleuritic pain, peripheral wedge lesion that may cavitate
Hydatid disease	Endemic exposure and characteristic cystic imaging

The pathology differential for cavitary lung lesions also includes malignancy, infarction, vasculitis, autoimmune disease, sequestration and septic emboli.

8. Essential investigations and expected results

A. Basic tests

Complete blood count
- Anemia, leukocytosis, eosinophilia in selected settings
ESR and CRP
- Nonspecific, useful for trend
Renal and liver function
- Important before anti-TB drugs and azole antifungals
Blood glucose and HbA1c
HIV test with consent
Nutritional assessment: BMI, albumin where indicated
Pulse oximetry at rest and on exertion

B. TB microbiology

What samples?

At least good-quality sputum samples, preferably early morning where locally recommended
Induced sputum if unable to expectorate
Bronchoscopy with BAL if sputum is negative/unavailable but suspicion persists

Tests

Rapid molecular test, such as Xpert MTB/RIF or equivalent NAAT
Smear microscopy
Mycobacterial culture
Drug-susceptibility testing, especially rifampicin resistance and broader DST according to local protocol

Q. Why is sputum smear alone inadequate?

Because smear cannot:

Confirm viable bacilli
Differentiate M. tuberculosis from NTM
Reliably establish drug susceptibility
Exclude active TB when negative

C. Evaluation for Aspergillus

Aspergillus IgG antibody: central test for CPA
Sputum fungal microscopy and fungal culture
BAL fungal culture if bronchoscopy is performed
Histopathology where lesion is biopsied
Serum/BAL galactomannan may help in selected patients but is not a stand-alone test for CPA
Serial chest X-rays or CT to establish progression

Q. How do you diagnose chronic pulmonary aspergillosis?

Answer:

“CPA is diagnosed by the combination of chronic symptoms or progressive radiological abnormality for at least 3 months, one or more compatible cavities with or without fungal ball or pleural thickening, microbiological or serological evidence of Aspergillus infection, usually positive Aspergillus IgG, and exclusion of alternative diagnoses, especially active TB and NTM disease.”

D. Bronchiectasis evaluation

Sputum Gram stain and bacterial culture
Mycobacterial and fungal cultures
HRCT chest
Consider immunological evaluation if diffuse/unexplained bronchiectasis, based on clinical context

E. Functional assessment

Spirometry with bronchodilator testing
Lung volumes and DLCO if available
Six-minute walk test
Arterial blood gas if hypoxemia or hypercapnia is suspected
Overnight oximetry/sleep assessment if clinically indicated

Possible patterns:

Obstructive
Restrictive
Mixed obstruction and restriction
Reduced DLCO with extensive parenchymal or pulmonary vascular involvement

F. Evaluation for pulmonary hypertension

ECG
Echocardiography
BNP/NT-proBNP in selected cases
CT may show enlarged pulmonary artery
Right-heart catheterization is the diagnostic reference test when confirmation would alter management

G. Evaluation of hemoptysis

CBC, platelets
PT/INR, aPTT, renal function
Crossmatch if bleeding is significant
Chest X-ray
Contrast CT/CT angiography, especially if recurrent or significant bleeding
Bronchoscopy when localization, airway clearance, endobronchial lesion assessment, or sampling is needed

9. Active TB versus inactive post-TB disease

Feature	Active TB more likely	Inactive post-TB sequelae more likely
Symptoms	Fever, night sweats, weight loss, worsening cough	Stable chronic exertional dyspnea/cough
Imaging	New or progressive infiltrate/cavity/tree-in-bud nodules	Stable fibrosis, calcification, volume loss
Microbiology	TB NAAT/culture positive	Negative TB microbiology
Inflammatory markers	May be elevated	Often normal or mildly elevated
Serial films	Progression	No progression
Response	Improves with appropriate therapy	Symptoms may persist due to fixed damage

Do not say: “The patient has old TB, therefore no sputum examination is required.”
Correct answer: “Any patient with prior TB who has new constitutional symptoms, new radiological lesions, or hemoptysis should be reassessed for active TB and other causes.”

10. Aspergilloma and chronic pulmonary aspergillosis

A. What is an aspergilloma?

An aspergilloma is a conglomerate of fungal hyphae, mucus, fibrin and cellular debris that colonizes a pre-existing lung cavity. It is also called a fungal ball or mycetoma.

B. Common pre-existing cavities

Post-TB cavity, most common in high-TB settings
Sarcoidosis
Bullae/emphysema
Prior lung abscess
Pneumoconiosis
Cystic bronchiectasis
Previously treated lung cancer cavity

C. Types of CPA

Simple aspergilloma
Chronic cavitary pulmonary aspergillosis
Chronic fibrosing pulmonary aspergillosis
Aspergillus nodules
Subacute invasive aspergillosis, more likely in immunocompromised patients

D. Simple aspergilloma versus CPA

Feature	Simple aspergilloma	Chronic pulmonary aspergillosis
Symptoms	None/minimal; may have hemoptysis	Chronic cough, fatigue, weight loss, dyspnea, hemoptysis
Cavity	Usually single and stable	One or multiple cavities, often progressive
Fungal ball	Common	May be present or absent
Radiological progression	Absent over observation period	Present over at least 3 months
Treatment	Observe if asymptomatic and stable; surgery in selected cases	Long-term oral antifungal therapy, usually a triazole

E. Why does aspergilloma cause hemoptysis?

Mechanical irritation, chronic inflammation, neovascularization and erosion of hypertrophied bronchial vessels around the cavity cause bleeding.

F. Why are antifungals not always effective in simple aspergilloma?

The fungal ball is relatively avascular. Drug penetration into the intracavitary fungal mass is limited. Antifungals are more useful in chronic cavitary CPA than in an isolated stable fungal ball.

11. Hemoptysis: emergency viva answers

Define life-threatening hemoptysis

There is no single universal volume threshold. It is better defined by airway compromise, hypoxemia, hemodynamic instability, rapid ongoing bleeding, or inability to clear blood from the airway, rather than a fixed milliliter volume.

Major causes in post-TB disease

Bronchiectasis with hypertrophied bronchial arteries
Active/recurrent TB
Aspergilloma or CPA
NTM infection
Bronchogenic carcinoma
Rasmussen aneurysm, which is a pulmonary artery pseudoaneurysm adjacent to a TB cavity
Coagulopathy or drugs that increase bleeding

Bronchial versus pulmonary artery circulation

Approximately 90% of major hemoptysis arises from the bronchial circulation, a systemic high-pressure circulation.
Pulmonary artery bleeding is less common but may occur with Rasmussen aneurysm.

Initial management of significant hemoptysis

Call for senior help, anesthetist, respiratory/interventional radiology team.
ABC approach.
Give oxygen and monitor saturation, ECG and blood pressure.
Secure intravenous access and send blood tests including group and crossmatch.
Stop/reverse anticoagulants when clinically appropriate.
Keep the bleeding side down if known, to protect the contralateral lung.
Consider airway protection and intubation with a large-bore endotracheal tube if bleeding threatens the airway.
Localize cause with CT angiography when the patient is stable enough.
Bronchial artery embolization is commonly the first definitive intervention for significant/recurrent bleeding.
Surgery is considered for localized disease with refractory/recurrent life-threatening bleeding or when a resectable cause such as localized aspergilloma is present and pulmonary reserve permits.

Q. What is the best next intervention in massive hemoptysis in this setting?

There is no one answer for every patient. Resuscitate and protect the airway first. After localization, bronchial artery embolization is often the preferred initial definitive procedure because many patients have limited pulmonary reserve and are poor surgical candidates.

12. Treatment of post-TB fibrocavitary disease

Principle

There is no drug that reverses established fibrosis. Management has four components:

Exclude and treat active infection.
Treat specific complications.
Improve respiratory function and quality of life.
Prevent progression and recurrent infection.

A. If active TB is confirmed

Treat according to the current national TB programme and drug-susceptibility results.
Do not use an old “retreatment category” regimen empirically.
Obtain rapid molecular testing and DST.
Ensure adherence support, adverse-effect monitoring, nutritional support and contact evaluation.
Consider drug-resistant TB if there was prior treatment failure, poor adherence, known exposure, or rifampicin resistance.

WHO recommends rapid molecular testing as an initial diagnostic test in persons with symptoms/signs of TB, as summarized in the current WHO TB fact sheet.

B. If there is stable inactive structural disease

Smoking cessation and avoidance of biomass/dust exposure
Vaccination according to local recommendations, including influenza and pneumococcal vaccination where indicated
Nutritional rehabilitation
Pulmonary rehabilitation
Chest physiotherapy and airway-clearance methods for bronchiectasis
Sputum culture-guided antibiotics for infective exacerbations
Bronchodilators if airflow obstruction and symptomatic benefit
Long-term oxygen therapy for documented chronic severe resting hypoxemia, after proper assessment
Monitor symptoms, exacerbations, saturation, spirometry and imaging when clinically indicated

C. Bronchiectasis management

Teach airway clearance technique
Adequate hydration and exercise
Send sputum for bacterial, mycobacterial and fungal culture before antibiotics whenever possible
Treat exacerbations according to culture and severity
Consider inhaled bronchodilator if obstructive physiology or breathlessness
Treat chronic Pseudomonas or frequent exacerbations according to bronchiectasis guidance and specialist assessment
Evaluate recurrent hemoptysis for bronchial artery embolization

D. Management of chronic pulmonary aspergillosis

Refer to respiratory medicine/infectious diseases.
Oral triazole therapy is standard for symptomatic or progressive CPA, commonly itraconazole or voriconazole, selected according to drug interactions, liver function, local availability and susceptibility.
Treatment is usually prolonged, commonly at least 6 months, with reassessment of symptoms, imaging, Aspergillus IgG trends where useful, drug levels for certain azoles, liver tests and toxicity.
Consider azole resistance when there is clinical or radiological deterioration despite adequate drug exposure.
Do not initiate prolonged antifungal therapy solely because a cavity is present. Establish CPA with clinical, radiological and microbiological/serological evidence.
Surgery may be appropriate for selected localized disease, particularly recurrent major hemoptysis, but risk is high in patients with extensive fibrosis or poor reserve.

E. Simple asymptomatic aspergilloma

Observation with serial symptoms and imaging can be appropriate if stable.
Surgical resection can be curative in carefully selected patients with adequate reserve and localized disease.
Significant/recurrent hemoptysis requires urgent assessment, often bronchial artery embolization as initial control.

F. Surgery in post-TB disease

Possible indications:

Localized aspergilloma with significant/recurrent hemoptysis
Localized destroyed lobe with repeated infection or severe hemoptysis
Persistent localized drug-resistant infection in selected cases
Bronchopleural fistula/empyema requiring surgical management
Suspicion of malignancy requiring diagnosis/resection

Preoperative assessment:

HRCT
Spirometry, DLCO
Predicted postoperative lung function
Perfusion assessment in selected patients
Echocardiography if pulmonary hypertension suspected
Nutritional and infection optimization

13. Pulmonary rehabilitation: a common modern viva question

Q. Why is pulmonary rehabilitation useful in PTLD?

Patients can have persistent dyspnea, deconditioning, muscle loss, anxiety and reduced exercise capacity even after microbiological cure. Pulmonary rehabilitation combines exercise training, breathing techniques, education, nutrition, and self-management.

Components:

Aerobic exercise
Strength training
Breathing exercises
Airway-clearance training
Nutrition support
Smoking cessation
Education about exacerbation recognition and inhaler use

Recent systematic reviews suggest pulmonary rehabilitation can improve lung function and quality of life in people with PTLD, but the evidence base and long-term implementation data remain limited. See the 2026 systematic review and meta-analysis and the 2025 lung-function meta-analysis.

14. Complications: must-know list

Complication	Clinical clue
Recurrent active TB	Fever, weight loss, new infiltrates, positive microbiology
Drug-resistant TB	Previous therapy, nonadherence, persistent disease, DST abnormality
Bronchiectasis	Daily purulent sputum, recurrent infection, crackles, hemoptysis
Aspergilloma	Intracavitary mobile mass, hemoptysis
Chronic pulmonary aspergillosis	Chronic symptoms, progressive cavities, positive Aspergillus IgG
NTM disease	Persistent cavitary/bronchiectatic disease, repeated NTM culture positivity
Bacterial infection/lung abscess	Fever, purulent sputum, air-fluid level
Hemoptysis	Any quantity, especially recurrent/large volume
Pneumothorax	Acute pleuritic pain, sudden dyspnea
Bronchopleural fistula/empyema	Persistent air leak, fever, pleural collection
Chronic hypoxemic respiratory failure	Cyanosis, low saturation, polycythemia
Type 2 respiratory failure	Somnolence, morning headache, hypercapnia
Pulmonary hypertension/cor pulmonale	Edema, raised JVP, loud P2, RV heave
Lung cancer	New/change in cavity or symptoms, mass, lymphadenopathy
Amyloidosis, rare	Renal or systemic features in long-standing suppurative disease

15. High-yield rapid-fire questions with answers

1. What does an upper-lobe fibrotic lesion with hilar elevation suggest?

Chronic volume loss due to fibrosis, commonly from prior TB.

2. Why are post-primary TB lesions usually apical?

Higher oxygen tension, relatively reduced lymphatic drainage, and regional ventilation-perfusion characteristics favor reactivation disease in upper lobes.

3. What is traction bronchiectasis?

Irreversible bronchial dilatation caused by surrounding fibrosis pulling the bronchial walls outward.

4. What is destroyed lung?

Severe unilateral or lobar parenchymal destruction with fibrosis, volume loss, bronchiectasis, vascular attenuation and recurrent infection after prior disease such as TB.

5. Is a cavity always active TB?

No. It may be healed, colonized by fungus, due to NTM, malignancy, abscess, vasculitis or other causes.

6. Is hemoptysis in old TB always due to aspergilloma?

No. Bronchiectasis and hypertrophied bronchial arteries are common causes. Active TB, cancer, NTM and Rasmussen aneurysm must also be considered.

7. What is Rasmussen aneurysm?

A pulmonary artery pseudoaneurysm adjacent to or within a chronic TB cavity, due to weakening of the arterial wall. It can cause massive hemoptysis.

8. What is the Monod sign?

An air crescent surrounding a fungal ball within a pre-existing cavity, seen in aspergilloma. The fungal ball may move with change in patient position.

9. Differentiate Monod sign from air-crescent sign.

Monod sign: air around a mobile intracavitary fungal ball in a pre-existing cavity.
Air-crescent sign: air between devitalized lung tissue and cavity wall, classically in recovery from invasive pulmonary aspergillosis.

10. What is the most useful serological test for CPA?

Aspergillus-specific IgG antibody.

11. Can sputum culture positive for Aspergillus alone diagnose CPA?

No. It may represent colonization. Diagnosis requires compatible symptoms, imaging and supporting microbiology/serology, with exclusion of competing diagnoses.

12. Can a patient have active TB and CPA together?

Yes. They can coexist. Do not assume one diagnosis excludes the other.

13. Why should NTM be considered?

NTM can cause chronic cavitary or nodular-bronchiectatic lung disease, especially in structurally damaged lungs. Repeated cultures and species identification are needed because one isolate may reflect contamination or colonization.

14. What sputum testing is required in a symptomatic post-TB patient?

Rapid molecular TB test, mycobacterial culture with DST, and bacterial/fungal cultures according to the presentation. Consider NTM evaluation.

15. What is the common pulmonary function pattern after TB?

Any of obstructive, restrictive or mixed defects may occur. Obstruction is often under-recognized due to small-airway and bronchiectatic damage.

16. What is the first step in any major hemoptysis?

Airway and hemodynamic stabilization, not immediate etiological treatment.

17. Which side should the patient with unilateral major hemoptysis lie on?

Bleeding lung down, if the bleeding side is known.

18. What is the preferred initial definitive procedure for recurrent significant bronchial-artery hemoptysis?

Bronchial artery embolization, when available and appropriate.

19. Why can surgery be difficult in post-TB fibrocavitary disease?

Dense pleural adhesions, poor lung reserve, distorted anatomy, bronchopleural fistula risk, postoperative respiratory failure and ongoing fungal infection risk.

20. Is empiric anti-TB treatment appropriate for every symptomatic post-TB cavity?

No. Obtain microbiological evidence and assess alternative diagnoses. Empiric treatment can delay diagnosis of CPA, NTM infection or malignancy and may promote toxicity/resistance.

16. Common examiner traps

Trap 1

“The cavity is old, so there is no active disease.”
Incorrect. Stability must be demonstrated clinically, radiologically and microbiologically when indicated.

Trap 2

“A fungal ball on X-ray means invasive aspergillosis.”
Incorrect. A fungal ball usually represents non-invasive colonization or CPA in a pre-existing cavity. Invasive aspergillosis occurs mainly in severely immunocompromised patients and has a different syndrome.

Trap 3

“All hemoptysis in TB comes from the pulmonary artery.”
Incorrect. Most significant hemoptysis is from hypertrophied bronchial arteries.

Trap 4

“Positive sputum for Aspergillus proves CPA.”
Incorrect. Colonization is possible. Correlate with symptoms, CT and Aspergillus IgG.

Trap 5

“Spirometry is unnecessary because the patient has fibrosis.”
Incorrect. PTLD often produces obstructive or mixed ventilatory defects that may respond symptomatically to inhaled therapy and rehabilitation.

Trap 6

“Persistent symptoms after TB treatment always mean treatment failure.”
Incorrect. Symptoms may be caused by fixed PTLD, bronchiectasis, CPA, COPD, pulmonary hypertension, depression, malnutrition, or recurrent infection.

Trap 7

“Give antifungal treatment to every post-TB cavity.”
Incorrect. Treat established CPA or another proven fungal syndrome, not a cavity alone.

17. Final diagnosis format

Use this structure:

“Post-tuberculosis fibrocavitary lung disease involving the ___ lobe/___ lung, with volume loss and traction bronchiectasis, complicated by ___, for example recurrent hemoptysis likely due to bronchiectasis/aspergilloma, chronic pulmonary aspergillosis, chronic respiratory failure, or cor pulmonale. I would rule out active drug-susceptible or drug-resistant TB, NTM infection and cavitating bronchogenic carcinoma.”

Examples:

“Post-TB right upper-lobe fibrocavitary disease with traction bronchiectasis and recurrent hemoptysis, with possible aspergilloma.”
“Bilateral post-TB fibrotic lung disease with mixed ventilatory defect and chronic hypoxemic respiratory failure.”
“Post-TB left upper-lobe cavity with chronic pulmonary aspergillosis, pending Aspergillus IgG and sputum microbiology, while excluding recurrent TB and NTM.”

18. Last-minute viva summary

Memorize these six lines:

Post-TB fibrocavitary disease is structural lung damage after treated TB, not proof of active TB.
Always distinguish healed disease from recurrent TB, drug-resistant TB, NTM, CPA and malignancy.
HRCT defines cavities, fibrosis, bronchiectasis, fungal ball and disease extent.
CPA requires chronic symptoms or progression, compatible imaging, evidence of Aspergillus, and exclusion of alternatives.
Most major hemoptysis is from bronchial arteries. Stabilize airway first and consider bronchial artery embolization.
Management combines treatment of active disease/complications with rehabilitation, airway clearance, smoking cessation, nutrition and assessment for respiratory failure or cor pulmonale.

Evidence update for exams: Recent systematic reviews reinforce the burden of impaired lung function after pulmonary TB and the frequent association of CPA with prior TB cavities. Relevant recent reviews include PTLD lung-function review, PMID 40412395 and CPA after TB review, PMID 40117217.

This is a shared conversation. Sign in to Orris to start your own chat.